ReviewCurrent opinion in pharmacology2012
Cholesterol and prostate cancer.
Review in Current opinion in pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
145 citing papers in PubMed, 5 syntheses or guidelines pooled it, 298 citations in OpenAlex.
- Assessing the relationship between cardiometabolic diseases and the risk of developing aggressive prostate cancer: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor.Cellular oncology (Dordrecht, Netherlands) · 2022Pooled it
- Pooled it
- Influence of statins in metastatic castration-resistant prostate cancer patients treated with new antiandrogen therapies: a systematic review and meta-analysis.Einstein (Sao Paulo, Brazil) · 2022Pooled it
- Statin Use and the Risk of Prostate Cancer Biochemical Recurrence Following Definitive Therapy: A Systematic Review and Meta-Analysis of Cohort Studies.Frontiers in oncology · 2022Pooled it
- Trial
- Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.Prostate cancer and prostatic diseases · 2018Trial
- Proteomic Analysis of Sphingolipid Metabolic Enzymes with Risk of Bladder Cancer Incidence and Mortality in the Atherosclerosis Risk in Communities Study.Cancer prevention research (Philadelphia, Pa.) · 2026Article
- MR-based techniques for imaging prostate cancer metabolism: current status and future perspectives.Abdominal radiology (New York) · 2026Review
- Cholesterol metabolism and aggressive prostate cancer: clarifying the signal from EPICAP.Translational andrology and urology · 2026Article
- Metabolic networks in the tumor microenvironment: roles of amino acid and lipid metabolism pathways in cancer progression and therapy.Experimental & molecular medicine · 2026Review
- Squalene synthase induces ERα expression via cholesterol supplementation to confer statin resistance in lung cancer cells.Cancer cell international · 2026Article
- Single-cell and spatial omics of metabolic-immune ecosystems in prostate cancer: from androgen signaling to therapy resistance.Frontiers in immunology · 2026Review
- The SOX10-ACAT2-Cholesterol Synthesis Axis Is Required for Melanoma Proliferation.International journal of biological sciences · 2026Article
- Tumor Cholesterol Synthesis, Statin Use, and Lethal Prostate Cancer.Molecular cancer research : MCR · 2025Article
- Sterol analysis in cancer cells using atmospheric pressure ionization techniques.Analytical and bioanalytical chemistry · 2025Article
- Reprogrammed Lipid Metabolism-Associated Therapeutic Vulnerabilities in Prostate Cancer.International journal of molecular sciences · 2025Review
- Article
- Pan-cancer analysis reveals the potential role of DHCR24 in bladder cancer via interactions with HRAS to facilitate cholesterol synthesis.Oncology letters · 2025Article
- Dietary saturated fatty acids and prostate cancer: insights into NF-κB pathway and lipid metabolism mechanisms.Discover oncology · 2025Review
85 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Prostate cancer risk can be modified by environmental factors, however the molecular mechanisms affecting susceptibility to this disease are not well understood. As a result of a series of recently published studies, the steroidal lipid, cholesterol, has emerged as a clinically relevant therapeutic target in prostate cancer. This review summarizes the findings from human studies as well as animal and cell biology models, which suggest that high circulating cholesterol increases risk of aggressive prostate cancer, while cholesterol lowering strategies may confer protective benefit. Relevant molecular processes that have been experimentally tested and might explain these associations are described. We suggest that these promising results now could be applied prospectively to attempt to lower risk of prostate cancer in select populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.